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BACKGROUND: Current markers available for screening normal populations and for monitoring prostate cancer (PCa) treatment lack
sensitivity and selectivity. Sphingosine-1-phosphate (S1P) is a circulating lipid second messenger involved in cell growth and migration,
the immune response, angiogenesis, and malignant transformation.
METHODS: Eighty-eight patients with localised, locally advanced, or metastatic PCa were recruited into this prospective single-centre
study. Plasma S1P levels were measured and compared with age-matched controls with benign prostate hyperplasia (BPH) (n¼ 110)
or with young healthy males with the very small chance of having PCa foci (n¼ 20).
RESULTS: Levels of circulating S1P were significantly higher in healthy subjects (10.36±0.69 pmol per mg protein, Po0.0001) and
patients with BPH (9.39±0.75, P¼ 0.0013) than in patients with PCa (6.89±0.58, ANOVA, P¼ 0.0019). Circulating S1P levels were
an early marker of PCa progression to hormonal unresponsiveness and correlated with prostate-specific antigen (PSA) levels and
lymph node metastasis. During the course of the study, nine patients have died of PCa. Importantly, their circulating S1P levels were
significantly lower (5.11±0.75) than in the surviving patients (7.02±0.22, n¼ 79, P¼ 0.0439). Our data suggest that the decrease in
circulating S1P during PCa progression may stem from a highly significant downregulation of erythrocyte sphingosine kinase-1 (SphK1)
activity (2.14±0.17 pmol per mg protein per minute in PCa patients vs 4.7±0.42 in healthy individuals, Po0.0001), which may be a
potential mechanism of cancer-induced anaemia.
CONCLUSION: This current study has provided a potential mechanism for cancer-related anaemia and the first evidence that plasma
S1P and erythrocyte SphK1 activity are the potential markers for the diagnosis, monitoring, and predicating for PCa mortality.
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In the Western World, prostate cancer (PCa) is now the most
commonly diagnosed non-cutaneous cancer in men and is the
second leading cause of cancer-related death (ACS, 2011). In the
United States, the lifetime probability of developing PCa is one in
six and it is estimated that 240 890 new cases of PCa will be
diagnosed in 2011, and there will be 33 720 deaths.
The only available blood test for PCa involves measuring
circulating levels of prostate-specific antigen (PSA), a protease
secreted by prostate cells. However, the prostate size, the presence
of benign prostate hyperplasia (BPH), and prostatitis are all known
to increase plasma levels of PSA resulting in only 33% of patients
above the currently accepted normal assay limit of 4.0 ngml1
having PCa. Conversely, up to 26% of patients with PSA
o4.0 ngml1 will have PCa (Thompson et al, 2004). In advanced
PCa, oncologists have mainly focused on PSA kinetics as a clinical
surrogate for outcome. However, although changes in PSA levels
do give a general prognosis they lack specificity for the individual
(Nelius and Filleur, 2009).
Sphingosine-1-phosphate is a lipid second messenger that
mediates processes with important roles in cancer progression,
angiogenesis, and cell motility, making it a key molecule in the
search for potential anticancer therapies. It is secreted into
the extracellular milieu and binds to specific transmembrane
G protein-coupled S1P receptors (S1PRs) to promote cell growth,
migration, chemotaxis, and inflammatory response.
Sphingosine kinase-1 (SphK1), the enzyme that generates S1P
has oncogenic properties (Xia et al, 2000), contributes to cancer
progression (Olivera et al, 1999), enhances tumour neovascular-
isation (Licht et al, 2003) and metastatic potential (Visentin et al,
2006) and is associated with a poor prognosis (Ruckhaberle et al,
2008). Recent work in our laboratory has demonstrated the role of
the SphK1/S1P pathway in PCa progression, disease recurrence,
and invasion into the extracapsular space (Malavaud et al, 2010).
In-vitro and in-vivo studies indicate a significant translational
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potential for the SphK1-targeting therapies (Pchejetski et al, 2005,
2008, 2010a; Sauer et al, 2009). Recent data show that FTY720
(Fingolimod), an agonist of S1PRs 1, 3, 4, and 5, which is clinically
used as a functional S1PR antagonist in treatment of multiple
sclerosis is the first clinically applicable SphK1 inhibitor and has
a radiosensitising potential providing improved local control for
prostate tumours (Pchejetski et al, 2010a).
Sphingosine-1-phosphate is present in the circulation in high
nanomolar concentrations, and erythrocytes (Hanel et al, 2007;
Ohkawa et al, 2008) are considered to be its major source.
The potential of S1P to have a role as a plasma marker of human
disease has been recently demonstrated by a study, which showed
that plasma S1P was elevated in patients with inflammatory
coronary artery disease (Deutschman et al, 2003). Circulating
levels of S1P were shown to be higher in mice with colon cancer
(Kawamori et al, 2006) and diabetes (Fox et al, 2011). In human
ovarian cancer patients, S1P levels were higher than in controls,
although they were not correlated with clinical stage (Sutphen
et al, 2004). We have recently associated a modulation of
circulating S1P with aromatase inhibitor-induced arthralgia
(Henry et al, 2010) and chemotherapy-induced weight gain
(Pchejetski et al, 2010b).
In this current report, we show that the levels of circulating S1P
in healthy individuals and patients with BPH are significantly
higher as compared with PCa. Furthermore, there is a significant
correlation between plasma S1P and clinical correlates in PCa
(PSA, PCa progression). Finally, our data provide the first evidence
that circulating S1P is a significant prognostic marker for PCa
mortality. We have identified erythrocytes as the major source of
S1P in our patients and shown a highly significant downregulation
of erythrocyte SphK1 activity in PCa patients compared with
control counterparts, suggesting a mechanism for PCa-induced
anaemia.
Overall, in this study we provide the first evidence that both
plasma S1P and erythrocyte SphK1 activity have potential as
diagnostic and prognostic markers for human PCa.
MATERIALS AND METHODS
Subjects and study design
In all, 116 PCa patients attending the Oncology Clinic, Hammer-
smith Hospital (London, UK) were approached and 88 PCa
patients were recruited into this prospective single-centre study
from February 2005 through October 2005 and their progress
tracked until October 2008 (Hammersmith hospitals Research
Ethics Committee approval 2000/5816). Sample size: an a priori
power analysis (SPSS software, SPSS Inc., Chicago, IL, USA)
indicated that n¼ 24 patients per group (e.g., disease stage or
treatment, independent samples) would be required to detect
correlation between variables (a¼ 5% probability type 1 error,
significance level; 95% power; 50% confidence interval, and 40%
standard deviation). To ensure a comprehensive analysis of
various types of PCa patients that attend a typical oncology clinic,
all eligible patients were approached (no stratification). Inclusion
criteria (CONSORT table in Supplementary Figure S1 and
Supplementary Table S1) was PSA levels o1000, absence of
multiple metastases. Control groups included 110 age-matched
patients with BPH, several patients with other cancers (Supple-
mentary Figure S2) as well as healthy volunteers (n¼ 20). At the
time of recruitment into the study (time¼ 0), TNM staging and
Gleason score assessment were performed, and 20ml of blood was
taken for blood counts, PSA and testosterone analysis, and serum
S1P measurement. CT scan, MRI, and biopsies followed by staging
were performed on all patients at initial staging. Patients were then
assigned a standard treatment according to their clinical assess-
ment (CONSORT table in Supplementary Figure S1). Patients were
re-evaluated 6 and 36 months after recruitment with PSA re-
measured. At these time points, S1P measurements were not taken
due to the limitation of the ethical approval to one intervention. At
the end of study, clinical end points (survival, stage, Gleason score,
metastasis, PSA, and testosterone) were re-assessed.
Reagents
[g-32P]-ATP (6000mCimmol1) was purchased from Perkin-Elmer
(Waltham, MA, USA) and silica gel 60 high-performance TLC
plates were from GE Healthcare (Waukesha, WI, USA). All other
chemicals and reagents were obtained from Sigma-Aldrich
(Carlsbad, CA, USA).
Plasma S1P analysis
Samples were collected in heparin tubes, put on ice, transferred to
the laboratory and plasma was separated by centrifugation,
aliquoted, and frozen. Plasma S1P content was measured similarly
to a method previously described by Edsall and Spiegel (1999).
Briefly, 50ml of serum was used for chloroform/methanol lipid
extraction in alkaline conditions. To aqueous phase buffer C
(200mmol L1 Tris–HCl (pH 7.4), 75mmol L1 MgCl2 in 2mol L
1
glycine (pH 9.0)) was added (1 : 6, v/v) and S1P was dephospho-
rylated by addition of 50 units per sample of alkaline phosphatase for
30min at 37 1C. Reaction was stopped by addition of HCl and
organic phase containing sphingosine was separated and evaporated.
Evaporated sphingosine was re-suspended in sphingosine kinase
buffer with 0.25% Triton X-100 and converted to S1P by addition of
recombinant bacterial SphK1 and [g-32P]ATP (10mCi, 1mmol L1)
containing 10mmol L1 MgCl2. Sphingosine-1-phosphate was
resolved by TLC, measured by autoradiography and expressed as
picomoles of S1P formed per mg of plasma protein.
Blood cell isolation and culture
Fresh blood samples from control subjects and PCa patients were
collected in heparin tubes. Plasma was separated by centrifugation;
peripheral blood mononuclear cells (PBMCs) and erythrocytes
were isolated by centrifugation on Ficoll-Hypaque gradients; snap
frozen in liquid nitrogen and kept at 80 1C or cultured in the
RPMI-1640 media with 10% FBS in the presence or absence of 30%
fresh plasma, fibroblasts, or PCa cells.
Cell lines
Human PCa PC-3 and DU145 cells were obtained from DSMZ
(Braunschweig, Germany) and the immortalised human dermal
fibroblasts fibroblast cell line HCA was obtained from Prof David
Kipling (Cardiff University). All cells were cultured between
passages 4 and 30 in RPMI-1640 containing 10% FBS. Cell lines
were routinely verified by morphology and growth curve analysis
and routinely screened for mycoplasma infection (MP0035
Lookout (R) mycoplasma PCR kit; Sigma-Aldrich). Cancer cell/
erythrocyte or fibroblast/erythrocyte co-culture experiments were
conducted in transwell inserts, in the presence of serum at 50%
confluence (for adherent cells).
SphK1 assay
The SphK1 assay was performed as previously described
(Bonhoure et al, 2006). Briefly, upon treatment, red blood cells
(RBCs) were harvested by centrifugation, washed with ice-cold
PBS, and cell pellets were re-suspended in SPHK buffer (20mM
Tris (pH 7.4)), 20% glycerol, 1mM b-mercaptoethanol,
1mM EDTA, 1mM sodium orthovanadate, 40mM b-glyceropho-
sphate, 15mM NaF, 1mM phenylmethylsulphonyl fluoride,
10mgml1 leupeptin, 10mgml1 aprotinin, 10mg/ml soybean trypsin
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inhibitor, and 0.5mM 4-deoxypyridoxine. After 10 s sonication,
samples were ultracentrifuged for 90min (105 000 g at 4 1C). The
SphK1 activity was determined in the cytosolic fractions in the
presence of 50 mM sphingosine (Avanti Polar Lipids, Alabaster,
AL, USA), 0.25% Triton X-100 and 20mM ATP containing 10 mCi
[g-32P]-ATP and 10mM MgCl2. The labelled S1P was separated by
thin layer chromatography on silica gel G60 with 1-butanol/
ethanol/acetic acid/water (80 : 20 : 10 : 10, v/v) and quantified by
autoradiography (ImageJ software, US NIH, Bethesda, MD, USA).
The SphK1-specific activity was expressed as picomoles of S1P
formed per min per mg of protein.
Determination of blood PSA and testosterone
PSA and testosterone serum levels were tested using AxSYM
PSA assay and AxSYM testosterone assay, respectively (Abbott
Laboratories, Maidenhead, UK).
Data representation and statistical analysis
Data analysis and presentation were performed in accordance
with CONSORT and REMARK recommendations and did not
include any multiple testing, variable selection, and cut point
optimisation. All measurements were performed in blinded
manner. The statistical significance of differences between
the means of two groups was evaluated by the non-parametric
Mann–Whitney U-test for categorical data, and the unpaired
two-tailed t-test was used for continuous data. When three or
more groups were analysed, one-way ANOVA test has been
used. Correlation analyses were performed using Pearson’s
correlation test.
RESULTS
Plasma S1P levels decrease during early PCa progression
and correlate with TN status
Circulating levels of S1P were measured in plasma samples of BPH
(n¼ 110) and PCa (n¼ 88) patients or control patients with no
history of cancer (n¼ 20), and correlated with the clinical stage
and grade. Levels of circulating S1P were significantly higher in
healthy subjects (10.36±0.69 pmol per mg protein, Po0.0001) and
patients with BPH (9.39±0.75, P¼ 0.0013) than in patients with
PCa (6.89±0.58) (ANOVA, P¼ 0.0019; Figure 1A). Importantly,
within the PCa group plasma S1P inversely correlated with the
stage of the disease (Figure 1B, ANOVA, P¼ 0.0456) with T1
patients having significantly higher levels of circulating S1P than
T2–T4 patients (T1: 8.21±0.44 vs T2: 6.52±0.36, P¼ 0.0085;
T3þ 4: 6.57±0.41 pmol per mg protein).
Decrease in plasma S1P has also significantly correlated with
positive lymph nodes (Figure 1C, 7.12±0.29 (negative, n¼ 73) vs
5.77±0.51 (positive, n¼ 15), P¼ 0.0308). Conversely, plasma S1P
was neither correlated with the presence of PCa metastasis
(Figure 1D, P¼ 0.2017), nor with Gleason sum (Figure 1E,
ANOVA, P¼ 0.9940). Plasma levels of S1P were only slightly
higher in patients with Gleason sum 5 in comparison patients with
Gleason sum 6 (7.09±0.65 vs 6.58±0.51, respectively, P¼ 0.6512).
Plasma levels of S1P were inversely correlated with plasma PSA
levels (Figure 2A). In patients with PSA410 ngml1, S1P levels
were significantly lower than in patients with the PSAo10 ngml1
(5.95±0.44 vs 7.08±0.32, respectively, P¼ 0.046). Similarly,
patients with S1Po7 pmol per mg protein hadBthree-fold higher
PSA levels than patients with S1P47 pmol per mg protein
(105.3±56.3 vs 37.28±30.06, ns; due to significant variation in
PSA levels between patients).
12 n.s.
n.s. n.s.
n.s.
***
**
**
*
10
8
S1
P,
 
pm
ol
 p
er
 m
g 
pr
ot
ei
n
S1
P,
 
pm
ol
 p
er
 m
g 
pr
ot
ei
n
S1
P,
 
pm
ol
 p
er
 m
g 
pr
ot
ei
n
6
4
2
0
Healthy Stage 1 Stage 2 Stage 
3+4
Negative
Lymph nodes
Positive
Negative
Metastases
Positive
9
8.5
8
7.5
7
6.5
6
5.5
5
4.5
4
9
8.5
7.4
7.2
6.8
6.6
6.4
6.2
5.8
5.6
6
7 8
7.5
7
6.5
6
5.5
5
5 6 7 8
Gleason sum
9
4.5
4
7.5
7
6.5
6
5.5
5
4.5
4
BPH PCa
Figure 1 Circulating S1P levels correlate with PCa onset and TN status. At the time of patients’ recruitment, a TNM and Gleason score assessment was
performed, and 20ml of blood was taken for blood counts, PSA and testosterone analysis, and plasma S1P measurement. Plasma S1P levels in healthy
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We have then grouped patients into those men with a relatively
indolent PCa (stage 1 or stage 2 PCa, and an average Gleason score
3þ 3) and compared them with patients with PCa of more
profound clinical significance defining this group as having either
stage 3 or stage 4 PCa, having high metastatic occurrence and a
Gleason score of 4þ 4 or greater. As shown in Figure 2B, patients
with indolent PCa had significantly higher S1P than patients with
clinically more aggressive disease (7.14±0.28 vs 5.93±0.55,
respectively, P¼ 0.0406).
We have then divided the patients on the groups with low
(o7 pmol per mg protein) and high (47 pmol per mg protein)
S1P. The ‘low S1P’ group contained a statistically greater
proportion of patients with stage 3 or 4 tumours (P¼ 0.0025)
and positive lymph nodes (P¼ 0.015) than the ‘high S1P’ group
(Figure 2C).
S1P correlates with plasma PSA, but is an earlier
marker of PCa
Circulating S1P correlates with plasma PSA (Figure 2A). Figure 3A
shows that PSA levels significantly correlated with tumour
progression (ANOVA, P¼ 0.0027); however, in contrast to S1P,
PSA was rather a late than an early marker gaining significance
only during progression from stage 3 to stage 4 (27.15±12.67 vs
278.50±117.92, respectively, P¼ 0.0463). Prostate-specific antigen
was not a significant predictor of Gleason sum (Figure 3B,
ANOVA, P¼ 0.4282), but was however significantly elevated in
patients with metastatic PCa (Figure 3C, 8.73±2.00 (negative) vs
323.20±127.8 (positive), Po0.0001).
It is well known that cancer treatments affect plasma
testosterone levels (Iversen et al, 1994), we have therefore
correlated plasma testosterone with S1P and clinical symptoms
only in patients that received no prior treatment (n¼ 39). Unlike
the PSA, circulating S1P levels did not correlate with plasma
testosterone levels (data not shown).
Plasma testosterone levels significantly correlated with PCa
stage (Figure 4A, ANOVA, P¼ 0.002); however similarly to PSA,
plasma testosterone levels in T1 and T2 patients were undistin-
guishable. In contrast to PSA, plasma testosterone was significantly
correlated with Gleason sum (Figure 4B, ANOVA, P¼ 0.0495) and
with the appearance of metastases (Figure 4C, 14.66±1.65
(negative) vs 3.770±2.78 (positive), P¼ 0.0047).
Plasma S1P has a prognostic value in human PCa
Prostate-specific antigen changes following the diagnosis of
malignancy are used to mark disease progression. We have
quantified 6 and 36 months PSA change in individual patients
and correlated these levels with time¼ 0 plasma S1P levels. Our
data show no significant correlation between PSA increase and
circulating S1P. However, although not significantly different,
patients with lower plasma S1P levels (o7) had nine-fold higher
average 6 months PSA increases than patients with higher S1P
levels (47) (Figure 5A, 25.30±13.66 vs 2.77±1.23, respectively,
P¼ 0.1543). A very similar pattern was observed after 36 months –
the PSA increase was B5.6-fold higher in patients with lower
pre-entry S1P levels (Figure 5B, 209.1±92.95 vs 37.36±22.79,
P¼ 0.098).
At the point of analysis, 9 patients have died of PCa and 79
patients were alive. Circulating S1P levels (at time 0) in the
deceased were 5.11±0.75 vs 6.84±0.22 pmol per mg protein in the
surviving patients (P¼ 0.0439), allowing to propose circulating
S1P as a significant prognostic marker predicating for PCa
mortality (Figure 5C).
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The reduction of circulating S1P in PCa patients correlates
with a decrease in erythrocyte SphK1 activity
Erythrocytes (Hanel et al, 2007; Ohkawa et al, 2008) have been
suggested as being the major source of circulating S1P. In PCa
patients, Pearson’s correlation testing showed a significant
correlation between S1P and white blood cells (WBCs) counts
(Supplementary Table S2), but not between S1P and , platelets
or haemoglobin. However, neither blood cell counts nor HgB
statistically correlated with stage, Gleason sum, and PSA levels
(Supplementary Table S2).
We have then isolated RBCs from healthy controls and
individuals with PCa and compared their SphK1 activity (normal-
ised per cellular protein content). Erythrocyte SphK1 activity
in PCa patients was 42-fold lower than in healthy controls
(2.14±0.17 pmol per mg protein per minute in PCa vs 4.71±0.42
in healthy individuals, Po0.0001) (Figure 6A). Importantly, there
were no overlaps between these groups, suggesting that erythro-
cyte SphK1 activity is a potential biomarker for PCa diagnosis.
This significant change of SphK1 activity was not reflected by
lower RBC counts in both PCa patients and healthy controls
(Supplementary Table S3), indicating that cancer presence may
modify erythrocyte cell SphK1 activity irrespective of erythrocyte
numbers. Of note, platelet and WBC counts and intracellular
SphK1 activity in PCa patients did not statistically differ from BPH
patients and healthy controls (data not shown).
We have then correlated RBCs SphK1 activity with circulating
levels of S1P. As shown in Supplementary Table S3, in both healthy
volunteers and PCa patients SphK1 activity in RBCs was correlated
with circulating S1P (P¼ 0.031 and P¼ 0.043, respectively).
Interestingly, co-culturing (using transwell inserts) of PC-3 PCa
cells with erythrocytes isolated from healthy controls has induced
a decline in erythrocyte SphK1 activity (Figure 6B). Similar data
were obtained with DU145 PCa cells, but not with human
fibroblasts (Supplementary Figure S3). These data indicated that
PCa cells may potentially secrete a factor that is downregulating
erythrocyte SPHK1 activity. Further experiments demonstrated
that similarly to incubation with PCa cells fresh plasma from PCa
patients’ inhibited SphK1 activity in RBCs derived from healthy
controls (Supplementary Figure S4). On the contrary, incubation
with plasma from healthy controls did not decrease SphK1 activity
in RBCs derived from PCa patients, which showed a tendency to
regain SphK1 activity (Supplementary Figure S4).
In PCa patients, circulating levels of S1P are unaffected by
age or treatment regimen
Circulating S1P has neither correlated with age (Supplementary
Figure S2A) nor with chemotherapy regimen (Supplementary
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Table S4, ANOVA, P¼ 0.079). Comparison of S1P values in
any of the two groups of patients did not show a statistically
significant difference. Furthermore, therapy-induced modifica-
tions of blood cell counts showed no correlation with changes
in plasma S1P (data not shown, in all cases Pearson’s P-value
was 40.1).
In addition to PCa patients, we have analysed plasma S1P in
patients with various cancers (Supplementary Figure S2B).
Although the number of recruited patients was insufficient to
provide any statistically significant data, our results show that
patients with each type of cancer have distinct levels of plasma S1P
with breast cancer patients having the lowest plasma S1P
(5.02±0.80) and patients with teratoma having the highest plasma
S1P (9.24±2.91), suggesting that this may reflect the way different
tumours induce paraneoplastic phenomenon.
DISCUSSION
In this current study, we provide compelling evidence that
circulating S1P and erythrocyte SphK1 activity are potential
diagnostic and prognostic markers for human PCa.
Our results indicate that plasma S1P levels were lower in
patients with PCa than in men with benign prostatic hypertrophy
or healthy controls and correlated with disease state (Figure 1).
Plasma S1P was also significantly lower in patients with positive
lymph nodes, but did not correlate with the presence of distant
metastases or Gleason score. These data suggest that the observed
drop in the circulating S1P is correlated with an early cancer
progression as opposed to acquiring of clinically metastatic status.
In line with this hypothesis, circulating S1P had a prognostic value
in distinguishing between those patients with indolent as
compared with clinically significant PCa (Figure 2C).
Plasma S1P was significantly correlated with plasma levels of
PSA (Figure 2), but not testosterone. In contrast to S1P, both PSA
(Figure 3) and testosterone (Figure 4) appeared to be rather late
predictors of PCa progression – no significant differences were
observed between patients with early stages of PCa. Conversely,
both markers were highly correlated with metastatic status of PCa
patients (Lin, 2009).
Longitudinal analysis (Figure 5) showed that patients with low
plasma S1P (o7 pmol per mg protein, n¼ 67) had 9-fold and 5.6-
fold higher average 6 and 36 months PSA increase than patients
with high S1P (47 pmol per mg protein, n¼ 21). While S1P
correlation with PSA increase was not statistically significant (due
to a considerable difference in PSA levels in different patients),
plasma S1P was significantly correlated with PCa patient mortality
(Figure 5C). These data clearly demonstrate that plasma S1P might
not only be an early marker of the PCa onset (Figure 1), but may
serve as a prognostic factor of the PCa outcome (Figure 5).
In isolated human samples, S1P shows significant stability.
While in live organism S1P has a very quick turnover (half-life
B15min; Venkataraman et al, 2008), prolonged storing of blood
samples or plasma at 4 1C did not alter S1P concentration (data
not shown).
The fact that circulating levels of S1P were lower in patients with
advanced PCa (Figure 1) ruled out the possibility of circulating S1P
to originate from cancer cells. Sphingosine-1-phosphate is present
in high concentrations in circulating haematopoietic cells, and in
our patients there was a positive correlation between plasma S1P
and WBC counts (Supplementary Table S2), although surprisingly
we have found no correlation with platelet or red cell numbers or
haemoglobin levels (Supplementary Table S2). We have shown that
blood cell counts per se were not relevant to PCa stage, Gleason
sum, and PSA levels (Supplementary Table S5). Dividing PCa
patients according to their age or therapies revealed that S1P has
neither correlated with age (Supplementary Figure S2) nor with
chemotherapy regimen (Supplementary Table S4), suggesting that
in these patients circulating S1P levels are determined rather by
cancer presence than by these factors.
We hypothesised that the observed changes in plasma S1P are
most probably a paraneoplastic phenomenon affecting S1P produc-
tion and secretion by blood cells. This hypothesis was further
confirmed by the fact that plasma S1P levels differed between
patients with different cancers (Supplementary Figure S2B).
Anaemia is a common problem in PCa patients, many of whom
are anaemic at presentation and experience its clinical manifesta-
tions (e.g., fatigue and dyspnoea). However, the exact mechanism
of cancer-induced anaemia is currently not known. Our data
provide the first evidence that cancer presence may significantly
downregulate erythrocyte SphK1 activity (Figure 6A) and this
significantly correlates with circulating S1P both in healthy
individuals and in PCa patients (Supplementary Table S3). This
coincides with a recent report showing that an SphK1 inhibitor
FTY720 can induce RBCs cell death (Eberhard et al, 2010).
Our data indicate that PCa cells may potentially secrete a factor
that decreases RBC SphK1 activity and this factor is present
in the plasma of PCa patients (Supplementary Figures 6B, S3,
S4, and S5).
Lower plasma levels of S1P may lead to several additional side
effects that may influence the course of the disease and the efficacy
of anticancer therapies. Sphingosine-1-phosphate was demon-
strated to have a key role in vascular permeability (Garcia et al,
2001) and recently low levels of circulating S1P were linked with
progression of leaky vessels (Camerer et al, 2009), a known
phenomenon in tumour biology that impairs chemotherapy access
to tumour cells. Furthermore, plasma S1P has been shown to have
a protective role on the cardiovascular system (Rodriguez et al,
2009), which may be particularly important in a view of a recent
report of increased relative risks of cardiovascular disease in all
men with PCa (Van Hemelrijck et al, 2010).
Overall, in this study we have identified plasma S1P as a new
diagnostic and prognostic marker for PCa. Importantly, the biggest
change in plasma S1P was detected in patients with the early stage
of PCa, who were not yet treated with any therapy. This suggests
that plasma S1P may be used as a potential biomarker for early
PCa, especially in a view that high throughput methods of its
analysis are available (Bielawski et al, 2006). While our data
indicate that in PCa patients circulating levels of S1P are
unaffected by age or treatment regimen, due to limited group
sizes the links between S1P and therapy should be investigated
further. In this study, regression and multivariate analyses were
not used as the small sample size would have limited statistical
power for these analyses. More studies in stratified groups should
be performed to identify the diagnostic/prognostic potential of
plasma S1P in various patients groups and in patients with other
cancers. We have found that plasma S1P is secreted from RBCs and
is decreased during the early PCa progression, which reflects a
functional change in the RBCs SphK1 activity and not RBC counts
in response to cancer presence. These data suggest that circulating
S1P levels may reflect early metabolic changes in PCa patients and
serve as independent predictors, specifically in younger patients
with aggressive tumours and low PSA counts. Further studies are
required to investigate the exact mechanism of paraneoplastic
changes in blood cell SphK1 activity and its implication in cancer
progression.
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